Skip to main content

Advertisement

Table 3 Incidence of renal function deterioration and adjusted hazard ratio for renal function deterioration by baseline CKD stage using allopurinol as reference

From: Impact of urate-lowering drugs on the progression and recovery from chronic kidney disease among gout patients

  Person-days of follow-up Number of patients Events of CKD progression Incidence rate (95% CI) per 1000 person-days Hazard ratio (95% CI)
Entire cohort 434,716 5860 741 1.70 (1.58–1.83)
Type of ULD
 Allopurinol 19,680 532 39 1.98 (1.36–2.60) Reference
 Febuxostat 83,022 1105 156 1.88 (1.58–2.17) 1.14 (0.80–1.66)
 Uricosuric agents 332,014 4223 546 1.64 (1.51–1.78) 0.92 (0.67–1.31)
eGFR ≥ 90
 Allopurinol 4031 113 11 2.73 (1.12–4.34) Reference
 Febuxostat 5861 85 27 4.61 (2.87–6.34) 1.99 (0.99–4.28)
 Uricosuric agents 97,969 1131 208 2.12 (1.83–2.41) 0.91 (0.51–1.82)
eGFR 60–89
 Allopurinol 6134 163 12 1.96 (0.85–3.06) Reference
 Febuxostat 9141 147 25 2.73 (1.66–3.81) 1.43 (0.72–2.99)
 Uricosuric agents 123,774 1626 225 1.82 (1.58–2.06) 1.12 (0.64–2.14)
eGFR 30–59
 Allopurinol 7873 204 14 1.78 (0.85–2.71) Reference
 Febuxostat 44,744 557 76 1.70 (1.32–2.08) 0.97 (0.55–1.84)
 Uricosuric agents 95,166 1257 97 1.02 (0.82–1.22) 0.93 (0.53–1.75)
eGFR 15–29
 Allopurinol 1642 52 2 1.22 (0.15–4.40) Reference
 Febuxostat 23,276 316 28 1.20 (0.76–1.65) 1.40 (0.33–10.15)
 Uricosuric agents 15,105 209 16 1.06 (0.54–1.58) 1.28 (0.30–9.34)